What are the guidelines for using Norethindrone (progestin) for contraception, menopausal symptoms, or endometriosis?

Norethindrone Guidelines for Contraception, Menopausal Symptoms, and Endometriosis

Contraception

Progestin-only pills containing norethindrone carry no increased stroke risk and represent a safer contraceptive option compared to combined hormonal contraceptives, particularly for women with cardiovascular risk factors. 1

Dosing and Administration

• Take one tablet daily at the same time every day without interruption between pill packs 2
• Continuous administration is essential—no pill-free intervals 2
• If a pill is taken ≥3 hours late, use backup contraception (condoms/spermicides) for the next 48 hours 2

Contraceptive Effectiveness and Stroke Risk Profile

• Effectiveness: <90% (lower than combined oral contraceptives at 93-97%) 1
• Zero increased stroke risk compared to combined hormonal contraceptives containing ethinyl estradiol, which carry mild to severe stroke risk depending on estrogen dose 1
• Particularly appropriate for women with hypertension, smoking history, or migraine with aura—conditions that contraindicate estrogen-containing contraceptives 1

Baseline and Ongoing Monitoring

• Pregnancy test and blood pressure measurement before initiation 3
• Annual blood pressure checks and clinical review for stable patients 3
• More frequent monitoring during initial therapy 3
• Pregnancy is an absolute contraindication (Category X) 3

Common Pitfalls

• Menstrual irregularities are the most common side effect—counsel patients extensively about breakthrough bleeding, which occurs in approximately 58% of users 2, 4
• Diarrhea/vomiting may reduce hormone absorption and contraceptive efficacy 2
• Drug interactions with rifampin, anticonvulsants (phenytoin, carbamazepine, topiramate), and St. John's Wort reduce effectiveness 2

---

Menopausal Hormone Therapy

For postmenopausal women with premature ovarian insufficiency or early menopause requiring hormone replacement, norethindrone serves as endometrial protection when combined with estrogen, with micronized progesterone as first-line and norethindrone as a second-line alternative.

Indications and Patient Selection

• Premature ovarian insufficiency (menopause before age 40) or early menopause (before age 45) 1
• Hormone therapy should continue until the average age of natural menopause (45-55 years) 1
• Women ≥60 years or >10 years post-menopause should avoid oral estrogen-containing therapy due to excess stroke and cardiovascular risk 1

Norethindrone Dosing for Endometrial Protection

Sequential regimens (preferred for inducing withdrawal bleeding):

• 5 mg daily for 12-14 days per 28-day cycle when combined with transdermal or oral estradiol 1

Continuous regimens (for avoiding withdrawal bleeding):

• Minimum 1 mg daily when combined with continuous estrogen 1

Progestin Selection Hierarchy

• First choice: Micronized progesterone 100-200 mg daily for 12-14 days per cycle due to lower cardiovascular and venous thromboembolism risk 1
• Second choice: Norethindrone 5 mg daily for 12-14 days per cycle (or 1 mg continuous) 1
• Avoid progestins with anti-androgenic effects (drospirenone, cyproterone) in women with iatrogenic premature ovarian insufficiency, as they may worsen hypoandrogenism and sexual dysfunction 1

Monitoring Requirements

• Annual clinical review for stable patients 3
• Liver function tests periodically, especially at doses ≥10 mg daily—consider every 3-6 months initially, then annually if stable 3
• Assess for breast cancer history before initiation (absolute contraindication) 3

Vasomotor Symptom Management

• Norethindrone acetate combined with ethinyl estradiol effectively reduces hot flash frequency and severity in a dose-dependent manner 5
• 1 mg norethindrone acetate/5-10 mcg ethinyl estradiol produces 84% reduction in hot flash frequency within 4 weeks 5
• Lower doses (0.5 mg/2.5 mcg) still provide significant benefit but with slower onset (5 weeks) 5

---

Endometriosis

Norethindrone acetate demonstrates high efficacy (94% overall pain relief) for symptomatic endometriosis with relatively mild side effects, making it a cost-effective treatment option.

Efficacy Data

• 92.3% relief of dysmenorrhea (48/52 patients) 4
• 89.2% relief of noncyclic pelvic pain (25/28 patients) 4
• 94.2% overall pain relief (49/52 patients) 4
• 84.5% treatment success rate when accounting for dropouts 4

Side Effects and Discontinuation

• Breakthrough bleeding affects 57.6% of patients but only causes 7.7% to discontinue 4
• Breast tenderness may occur but rarely leads to discontinuation 4
• Overall dropout rate for side effects is low (approximately 10%) 4

Clinical Considerations

• Norethindrone acetate provides a cost-effective alternative to GnRH agonists or surgical management 4
• Particularly useful for women desiring medical management before considering surgical intervention 4

---

Critical Drug Interactions and Contraindications

Absolute Contraindications

• Pregnancy (Category X) 3, 2
• History of breast cancer 3
• New-onset or worsening migraine with recurrent, persistent, or severe pattern requires discontinuation 2

Significant Drug Interactions Reducing Efficacy

• Rifampin, barbiturates, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate 2
• Anti-HIV protease inhibitors (variable effects on hormone levels) 2
• St. John's Wort (induces hepatic enzymes) 2

Laboratory Test Alterations

• Decreased sex hormone-binding globulin (SHBG) 2
• Decreased thyroxine concentrations due to reduced thyroid binding globulin 2